Sangamo Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Sangamo Therapeutics

01/11/2023 21:03

* Sangamo Therapeutics Inc  SGMO.OQ  reported a quarterly
adjusted
loss of 59 cents​​ per share for the quarter ended in September,
lower than the same quarter last year, when the company reported
EPS of -34 cents.  The mean expectation of ten analysts for the
quarter was for a loss of 32 cents per share. Wall Street
expected results to range from -39 cents to -26 cents per share.
    * Revenue fell 64.5% to $9.40 million from a year ago;
analysts
expected $10.40 million. 
    * Sangamo Therapeutics Inc shares had risen by 5.1% this
quarter and lost 79.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 2.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Sangamo
Therapeutics Inc is $6.50 
This summary was machine generated from LSEG data November 1 at
09:02 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.32          -0.59          Missed
 Jun. 30 2023      -0.34          -0.66          Missed
 Mar. 31 2023      -0.33          0.12           Beat
 Dec. 31 2022      -0.36          -0.32          Beat